Profile data is unavailable for this security.
About the company
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. It markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.
- Revenue in USD (TTM)78.06m
- Net income in USD-8.36m
- Incorporated2001
- Employees107.00
- LocationSanara Medtech Inc1200 Summit Avenue, Suite 414FORT WORTH 76102United StatesUSA
- Phone+1 (817) 529-2300
- Websitehttps://sanaramedtech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scpharmaceuticals Inc | 30.28m | -80.12m | 173.10m | 135.00 | -- | 5.64 | -- | 5.72 | -1.91 | -1.91 | 0.7417 | 0.6137 | 0.262 | 0.7268 | 4.52 | 224,281.50 | -69.31 | -38.23 | -78.18 | -42.31 | 69.72 | -- | -264.60 | -1,360.16 | 6.89 | -8.42 | 0.6246 | -- | -- | -- | -48.79 | -- | -- | -- |
| Mediwound Ltd | 20.14m | -19.97m | 180.78m | 100.00 | -- | 8.71 | -- | 8.98 | -2.16 | -2.16 | 2.18 | 1.92 | 0.3311 | 5.53 | 6.55 | 201,410.00 | -32.83 | -24.48 | -49.28 | -32.92 | 13.25 | 43.27 | -99.17 | -38.43 | 1.51 | -3.26 | 0.2623 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| Inhibrx Biosciences Inc | 1.73m | 1.64bn | 202.37m | 166.00 | 0.117 | 1.13 | 0.123 | 116.71 | 119.47 | 119.47 | 0.0499 | 12.33 | 0.0058 | -- | 4.41 | 10,445.78 | 552.15 | -77.06 | 637.71 | -93.91 | -- | -- | 94,778.95 | -1,590.91 | -- | -45.76 | 0.00 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
| Biostem Technologies Inc | 210.39m | 14.32m | 219.71m | 67.00 | 21.41 | 9.65 | 15.11 | 1.04 | 0.6302 | 0.6302 | 10.58 | 1.40 | 3.82 | 8.46 | 5.01 | -- | 26.03 | -- | 135.75 | -- | 94.84 | -- | 6.81 | -- | 1.23 | 27.98 | 0.1576 | -- | -- | -- | -- | -- | -- | -- |
| Lifecore Biomedical Inc | 128.45m | 5.71m | 257.05m | 524.00 | 188.96 | -- | 17.86 | 2.00 | 0.0369 | 0.0595 | 3.82 | 1.28 | 0.5217 | 2.01 | 4.96 | 245,124.00 | 2.32 | -5.91 | 2.74 | -8.33 | 34.65 | 31.01 | 4.45 | -19.16 | 0.803 | 0.125 | 0.7641 | -- | 24.20 | -25.46 | 114.53 | 34.47 | -16.72 | -- |
| Precigen Inc | 3.96m | -139.56m | 257.82m | 202.00 | -- | 4.78 | -- | 65.06 | -0.5479 | -0.5479 | 0.0154 | 0.1891 | 0.0289 | -- | 5.40 | 19,618.81 | -101.81 | -31.50 | -126.84 | -38.63 | -12.44 | 44.00 | -3,521.68 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Eton Pharmaceuticals Inc | 34.68m | -5.48m | 277.74m | 30.00 | -- | 17.38 | -- | 8.01 | -0.2135 | -0.2135 | 1.34 | 0.6186 | 1.03 | 9.44 | 7.63 | 1,155,900.00 | -16.27 | -46.22 | -29.44 | -58.20 | 59.30 | 72.16 | -15.81 | -76.86 | 1.41 | -- | 0.2052 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
| Sanara Medtech Inc | 78.06m | -8.36m | 326.44m | 107.00 | -- | 8.20 | -- | 4.18 | -0.9871 | -0.9871 | 9.24 | 4.55 | 0.9518 | 1.91 | 8.39 | 729,503.40 | -10.33 | -17.73 | -12.37 | -22.07 | 90.16 | 88.08 | -10.86 | -17.13 | 2.02 | -3.44 | 0.4326 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Amylyx Pharmaceuticals Inc | 196.49m | -259.47m | 355.76m | 384.00 | -- | 1.81 | -- | 1.81 | -3.82 | -3.82 | 2.87 | 2.86 | 0.5479 | 2.56 | 12.64 | 511,679.70 | -72.35 | -- | -84.00 | -- | 78.88 | -- | -132.05 | -- | 4.55 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| Revance Therapeutics Inc | 247.00m | -180.81m | 402.83m | 597.00 | -- | -- | -- | 1.63 | -1.91 | -1.95 | 2.55 | -1.55 | 0.497 | 1.03 | 6.71 | 413,740.40 | -36.38 | -55.55 | -43.47 | -63.20 | 72.61 | -- | -73.20 | -304.96 | 3.05 | -15.40 | 1.58 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Aquestive Therapeutics Inc | 58.90m | -35.19m | 411.21m | 135.00 | -- | -- | -- | 6.98 | -0.4514 | -0.4514 | 0.7297 | -0.4982 | 0.6954 | 2.56 | 6.46 | 436,296.30 | -41.55 | -76.63 | -54.06 | -123.85 | 69.39 | 64.24 | -59.75 | -102.95 | 5.91 | -2.72 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| Rigel Pharmaceuticals Inc | 157.47m | 3.88m | 441.08m | 147.00 | 115.56 | -- | 76.07 | 2.80 | 0.2167 | 0.2167 | 8.98 | -0.831 | 1.24 | 3.06 | 5.82 | 1,071,252.00 | 3.05 | -28.82 | 5.10 | -47.26 | 89.43 | 97.88 | 2.46 | -35.76 | 1.87 | 1.69 | 1.32 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| SIGA Technologies Inc | 173.73m | 85.71m | 447.49m | 45.00 | 5.28 | 2.64 | 5.19 | 2.58 | 1.19 | 1.19 | 2.42 | 2.37 | 0.9823 | 0.5034 | 17.25 | 3,860,698.00 | 48.46 | 22.34 | 57.01 | 27.56 | 81.60 | 88.65 | 49.33 | 41.14 | 5.32 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| Xeris Biopharma Holdings Inc | 187.36m | -63.11m | 452.96m | 377.00 | -- | -- | -- | 2.42 | -0.4388 | -0.4388 | 1.30 | -0.1901 | 0.5775 | 0.8389 | 4.30 | 496,978.80 | -19.45 | -43.60 | -26.81 | -56.57 | 81.36 | 78.23 | -33.69 | -143.08 | 1.29 | -1.86 | 1.14 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| Theravance Biopharma Inc | 63.19m | -49.40m | 470.14m | 99.00 | -- | 2.55 | -- | 7.44 | -1.01 | -1.01 | 1.29 | 3.78 | 0.1642 | -- | 3.73 | 638,303.00 | -12.84 | -40.51 | -13.71 | -48.50 | -- | -- | -78.18 | -305.27 | -- | -- | 0.1379 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
Data as of Nov 22 2024. Currency figures normalised to Sanara Medtech Inc's reporting currency: US Dollar USD
7.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2024 | 188.46k | 2.16% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 165.65k | 1.89% |
| Geode Capital Management LLCas of 30 Sep 2024 | 88.27k | 1.01% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 58.69k | 0.67% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 40.46k | 0.46% |
| Janney Montgomery Scott LLC (Investment Management)as of 30 Sep 2024 | 32.85k | 0.38% |
| World Investment Advisors LLCas of 30 Sep 2024 | 21.10k | 0.24% |
| Citadel Securities LLCas of 30 Sep 2024 | 20.49k | 0.23% |
| RBC Capital Markets LLC (Investment Management)as of 30 Sep 2024 | 18.94k | 0.22% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 14.00k | 0.16% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
